Old Web
English
Sign In
Acemap
>
authorDetail
>
Cory Marvis
Cory Marvis
Roswell Park Cancer Institute
Lymphoma
Bortezomib
Medicine
Chemotherapy
Immunology
3
Papers
6
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Entinostat (SNDX-275), a Novel DAC Inhibitor, Is Highly Effective in Rituximab- [Chemotherapy]-Sensitive or Rituximab-[Chemotherapy]-Resistant Lymphomas and Has Synergistic Anti-Tumor Activity When Combined with Bortezomib.
2009
Blood
Umeer Ashraf
Myron S. Czuczman
Cory Marvis
John F. Gibbs
Francisco J. Hernandez-Ilizaliturri
Show All
Source
Cite
Save
Citations (2)
The DAC Inhibitor, LBH589, Is Highly Effective in Both Rituximab-Sensitive and Rituximab-Resistant Lymphomas and Enhances the Anti-Tumor Activity of Bortezomib, Other Chemotherapy Agents, and Anti-CD20 Monoclonal Antibodies.
2009
Blood
Francisco J. Hernandez-Ilizaliturri
Cory Marvis
Ilir Maraj
Mohammad M Chisti
John F. Gibbs
Myron S. Czuczman
Show All
Source
Cite
Save
Citations (1)
Obatoclax and Bortezomib Therapy Results in Disruption of the p53-Mediated Apoptosis/Autophagy Pathway and Is Associated with Potent Synergistic Anti-Tumor Activity against Rituximab-Chemotherapy-Sensitive and -Resistant B-Cell Lymphoma.
2009
Blood
Francisco J. Hernandez-Ilizaliturri
Ping-Chiao Tsio
Ryan Campagna
Cory Marvis
Wasif Riaz
Elizabeth Gruber
John F. Gibbs
Myron S. Czuczman
Show All
Source
Cite
Save
Citations (3)
1